The federal government recently released information on the total purchases that hospitals, health centers, and clinics made through the 340B drug pricing program in 2022. The Health Resources & Services Administration (HRSA) reported that these purchases reached $53.7 billion, meaning 340B covered entities spent $9.8 billion more on 340B drugs than they did in 2021. This … [Read more...]
Ideas for 340B Changes Could Lead to Legislation
Amid complaints about unilateral drug company restrictions on the 340B drug pricing program and mounting pressure from industry-backed advocates for even more 340B changes to favor drugmakers, a bipartisan group of six U.S. senators have taken a proactive step by asking for ideas to ensure “stability” for 340B. This move came in the form of a request for information (RFI) … [Read more...]
Help From 340B After a Rare Diagnosis and an Unaffordable Bill
Nov. 27, 2023— Gary Chandler was in good company when he visited Ascension Via Christi St. Francis in Wichita, Kansas, because he was feeling unwell. One-quarter of patients at the health system’s three hospitals in the Wichita area are on Medicaid or are uninsured, like Chandler was when he came in. But his diagnosis was much more uncommon – aplastic anemia, a rare blood … [Read more...]
Research Illustrates Critical Role 340B Plays for Rural Hospitals and Patients
Sept. 7, 2023— Recent peer-reviewed research illustrates one of the many ways 340B savings bolster the nation’s rural hospitals and the communities and patients who rely on them for care. The findings help enrich a deep and growing evidence base for the vital role 340B is playing in American health care. Researchers from the University of Arkansas and the University of … [Read more...]